Carlsmed
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1800 Aston Ave Ste 100, Carlsbad, Califo...Phone Number
(760) 766-1923Website
www.carlsmed.comRevenue
$56.4 MillionStock Symbol
CARLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Carlsmed
Carlsmed's mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company's aprevo ® devices are personalized to improve the standard of care for the surgical treatment of adults with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create aprevo ® spine fusion devices to align with the surgeon's goals for each patient.Explore more
Carlsmed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Carlsmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Carlsmed has recently received funding, and reach out quickly before it becomes old news!
Check out if Carlsmed is spiking on competitors!
Product Launch: Get notified when Carlsmed launches new products
Earning: See what the market has to say on Carlsmed recently announced quarterly report
Carlsmed, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Carlsmed has new funding data
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Carlsmed
Click to see if Carlsmed had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Carlsmed
Find more new buyers
Compare Similar Companies to Carlsmed
Compare insights from companies similar to Carlsmed, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Carlsmed is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Carlsmed is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Carlsmed.
Carlsmed financials insights
Gather financial insights about Carlsmed, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$2.5M
Series A
$10M
2022
Series B
$30M
2024
Series C
$52.5M
2025
IPO
$100M
Carlsmed Tech Stack
A closer look at the technologies used by Carlsmed
Most Recent Scoops
Earnings
Carlsmed has reported a gross margin of approximately 77% for Q1 2026, increasing from 76% in H2 2025 and 74% in H1 2025, with the company citing AI-enabled efficiencies and fixed cost absorption as drivers of continued durability in the mid-to-high 70% range.
Earnings, Artificial Intelligence, Finance
Person-Based
Events, Healthcare Technology
Open Position
Person-Based
Executive Moves, Earnings, Finance
Open Position
Carlsmed News & Media
[Form 4] CARLSMED, INC. Insider Trading Activity - Stock Titan
CARLSMED, INC. director Kevin C. O’Boyle received a grant of 13,698 shares of Common Stock as a stock award with no cash price per share. Following this grant, he directly holds 31,031 common shares. The award is structured as restricted stock units that each convert into one share upon vesting.CARLSMED (CARL) director Jonathan Root awarded 13698 RSUs and updates holdings
CARLSMED director Jonathan D. Root receives 13,698 RSUs vesting by June 3, 2027 and reports 497,697 directly held shares, plus additional indirect holdings through U.S. Venture Partners funds with disclaimed beneficial ownership.Carlsmed Q1 Earnings Call Highlights
Carlsmed (NASDAQ:CARL) reported first-quarter 2026 revenue of $16.1 million, up 58% from $10.2 million in the prior-year period, as the company highlighted continued surgeon adoption of its patient-specific “aprevo” spine fusion procedures and ongoing efficiency gains in its digital production systeCarlsmed (CARL) Q1 2026 Earnings Transcript
Need a quote from a Motley Fool analyst? Joining me on today's call are Michael Cordonnier, chairman and chief executive officer, and Leonard Greenstein, chief financial officer. Before we begin, I would like to caution that comments made during this call will include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Carlsmed
Sign Up For FreeTo access detailed company insights
Carlsmed's mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The company's aprevo ® devices are personalized to improve the standard of care for the surgical treatment of adults with spinal malalignment. Carlsmed uses patient data and proprietary digital technologies to create aprevo ® spine fusion dev... Read More
